首页> 美国卫生研究院文献>Journal of Experimental Clinical Cancer Research : CR >Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
【2h】

Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors

机译:DNA甲基转移酶和组蛋白脱乙酰基酶抑制剂对三阴性乳腺癌细胞上皮间质转化的表观遗传重编程

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTriple negative breast cancer (TNBC) is an aggressive neoplasia with no effective therapy. Our laboratory has developed a unique TNBC cell model presenting epithelial mesenchymal transition (EMT) a process known to be important for tumor progression and metastasis. There is increasing evidence showing that epigenetic mechanisms are involved in the activation of EMT. The objective of this study is to epigenetically reverse the process of EMT in TNBC by using DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi).
机译:背景三阴性乳腺癌(TNBC)是一种积极的肿瘤,没有有效的治疗方法。我们的实验室已经开发出独特的TNBC细胞模型,该模型可呈现上皮间质转化(EMT),该过程已知对肿瘤的进展和转移至关重要。越来越多的证据表明,表观遗传机制与EMT的激活有关。这项研究的目的是通过使用DNA甲基转移酶抑制剂(DNMTi)和组蛋白脱乙酰基酶抑制剂(HDACi)表观遗传逆转TNBC中EMT的过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号